Recruiting
Phase 3

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Sponsor:

Novartis Pharmaceuticals

Code:

NCT05739383

Conditions

Primary Prevention of Atherosclerotic Cardiovascular Disease

Eligibility Criteria

Sex: All

Age: 40 - 70+

Healthy Volunteers: Not accepted

Interventions

Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL

Placebo in 1.5ml

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information